Compare ROAD & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROAD | LNTH |
|---|---|---|
| Founded | 2001 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.5B |
| IPO Year | 2018 | 2014 |
| Metric | ROAD | LNTH |
|---|---|---|
| Price | $113.66 | $103.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $127.80 | $87.00 |
| AVG Volume (30 Days) | 513.2K | ★ 898.9K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | N/A |
| EPS | 0.47 | ★ 1.80 |
| Revenue | ★ $785,679,000.00 | $343,374,000.00 |
| Revenue This Year | $27.79 | N/A |
| Revenue Next Year | $10.29 | $14.19 |
| P/E Ratio | $224.89 | ★ $57.96 |
| Revenue Growth | 0.31 | ★ 3.62 |
| 52 Week Low | $93.22 | $47.27 |
| 52 Week High | $151.00 | $104.50 |
| Indicator | ROAD | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 68.01 |
| Support Level | $105.97 | $93.33 |
| Resistance Level | $124.14 | N/A |
| Average True Range (ATR) | 5.52 | 3.52 |
| MACD | -0.32 | -0.00 |
| Stochastic Oscillator | 55.80 | 92.79 |
Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.